What Skye Biologics does

Skye Biologics Holdings, LLC is a privately held regenerative medicine company headquartered in El Segundo, California, that develops, processes, and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue. Its core technology, the proprietary HydraTek® BioAware® preservation system, processes placental connective tissue matrix without lyophilization, heat-baking, or chemical cross-linking, preserving natural biomechanical structure and enabling room-temperature storage with a five-year shelf life. The commercial portfolio spans three categories: advanced wound care products (WoundFix™, WoundPlus™, E-Graft™), surgical barrier membranes (ActiveBarrier® 200 and 2000), and ocular allografts (OculoMatrix® and VisiDisc® in thin and thick configurations). The company serves orthopedic, spine, sports medicine, ophthalmology, wound care, urology, gynecology, plastic surgery, and general surgery specialists across the United States and selectively in Canada, with a stated pipeline of regenerative therapeutics targeting musculoskeletal and high-unmet-need indications.

The company operates a vertically integrated supply chain through majority ownership of Human Regenerative Technologies (HRT), an AATB-licensed tissue bank that processes its allograft products. Skye generates revenue through one-time sale of tissue allograft units via a hybrid go-to-market combining direct sales to physicians and hospitals, independent sales representatives and distributors, approved contracts at regional, national, and government facilities, and quote-based phone/email ordering supported by dedicated physician and customer portals. A physician-collaboration patient registry of 5,000+ patients underpins clinical evidence generation, and the company cites FDA HCT/P compliance plus state tissue processor licenses in seven jurisdictions as its regulatory foundation.

Name

Skye Biologics

Legal name

Skye Biologics Holdings, LLC

Website

https://skyebiologics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Skye Biologics is a privately held regenerative medicine company that develops and commercializes ECM tissue allograft products from age-zero placental tissue using its proprietary HydraTek® preservation process, serving wound care, surgical, and ocular specialists across the United States.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Tissue Allografts

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine
• Tissue allografts
• Wound care products
• Extracellular matrix
• Amniotic membrane

Headquarters

HQ city

El Segundo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Tissue Allograft Products: Skye Biologics commercializes ECM allograft products including wound care products (WoundFix™, WoundPlus™, E-Graft™), surgical membranes (ActiveBarrier® 200, ActiveBarrier® 2000), and ocular products (OculoMatrix®, VisiDisc®). Products are sold as one-time tissue transplants for surgical and wound care applications.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Skye Biologics processes and commercializes extracellular matrix (ECM) tissue allograft products derived from age-zero human placental tissue using its proprietary HydraTek® BioAware® preservation technology. The portfolio includes Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™), Surgical Products (ActiveBarrier® 200 and 2000), and Ocular Products (OculoMatrix® and VisiDisc® in thin and thick configurations), sold to physicians, hospitals, and healthcare facilities.

Product overview

Skye Biologics is a vertically integrated regenerative medicine company commercializing ECM (extracellular matrix) allograft products preserved using its proprietary HydraTek® technology. The product portfolio spans three main categories: Advanced Wound Products (WoundFix™, WoundPlus™, E-Graft™) for acute and chronic wound management; Surgical Products (ActiveBarrier® 200, ActiveBarrier® 2000) for protective barrier applications; and Ocular Products (OculoMatrix® & VisiDisc® in Thin and Thick configurations) for ophthalmic procedures. All products utilize placental tissue from age-zero donors, processed through the BioAware® preservation system to maintain natural tissue structure and integrity.

Differentiator

Problem solved

Functional benefit

Brands

• HydraTek®: Proprietary tissue processing technology that preserves extracellular matrix (ECM) and produces the industry's most advanced allograft products with BioAware® technology
• BioAware®
• WoundFix™
• WoundPlus™
• E-Graft™
• ActiveBarrier®
• OculoMatrix®
• VisiDisc®
• Excellerate®

Products and services

• WoundFix™ Dehydrated amniotic membrane tissue allograft intended for homologous use as wound coverings in the management of acute and chronic wounds.
• WoundPlus™ Dehydrated amniotic membrane tissue allograft with natural rippled surface that can make it more ideal for self-adherence, intended for homologous use as wound coverings.
• E-Graft™ Dehydrated amniotic membrane tissue allograft with natural macro-texture surface that may assist in better adherence to the wound, intended for homologous use as wound coverings.
• ActiveBarrier® 200 Thick surgical membrane allograft (200 microns) with robust handling characteristics, preserving complete ECM via HydraTek® process. Provides natural adherence without need for sutures or fixation and can be applied in either direction.
• ActiveBarrier® 2000 Thickest surgical membrane allograft from Skye, providing robust handling and alternative options. Can be sutured if desired. Fresh-frozen storage required.
• OculoMatrix® & VisiDisc® Thin Thinner amniotic membrane graft (45 microns) derived from amnion membrane, providing versatile graft for most applications with ideal handling dry or wet.
• OculoMatrix® & VisiDisc® Thick Chorion-based amniotic membrane graft (200 microns) providing alternative handling characteristics and improved visibility for minimally invasive applications.

Quantifiable outcome

• Over 250,000 tissue-repair treatments performed nationwide with first generation tissue implants
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Human Regenerative Technologies (HRT)coreOthersHRT is a sister company and AATB licensed tissue bank that processes tissue allograft products for Skye Biologics through its HydraTek® technology. Skye Biologics Holdings became the majority owner of HRT in December 2018. HRT serves as the primary allograft tissue processor for Skye Orthobiologics, LLC's placental and amniotic tissue allograft offering.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Smith+Nephew: Global medical device incumbent with a substantial advanced wound management portfolio that overlaps with Skye's wound care allografts. Significantly larger scale and broader product breadth; competing primarily through conventional wound dressings and skin substitutes.
• Convatec: Convatec is a global wound care and ostomy incumbent with adjacent biologic and skin-substitute offerings (e.g., InnovaMatrix). Larger scale than Skye; competes for the same hospital and outpatient wound care budgets.
• Coloplast: Coloplast operates a sizable wound and skin care business alongside its core ostomy and continence franchises. Comparable in wound care end markets but at materially larger scale and broader portfolio.
• Integra LifeSciences: Integra is a diversified medical device incumbent with a regenerative technologies segment including AmnioExcel and PriMatrix wound care allografts, plus a broad neurosurgery/orthopedics portfolio. Comparable on wound and surgical membrane products but operates at much greater scale and breadth.

Emerging players

• Surgenex: Surgenex markets amniotic membrane and umbilical cord allografts (e.g., SurForce, SurGraft) targeting wound care, orthopedics, and pain management. Smaller and emerging peer with overlapping placental allograft technology and customer segments.
• Cook Biotech: Cook Biotech develops and manufactures extracellular matrix-based medical devices (e.g., OASIS wound matrix, Biodesign surgical products). Comparable ECM/biologic platform serving wound care and surgical specialties.

Direct peers

• Celularity: Celularity develops and commercializes placental-derived allogeneic cellular and tissue products for wound care and regenerative medicine. Directly comparable technology base (placental tissue) and overlapping wound care commercial focus.
• Anika Therapeutics: Anika commercializes regenerative therapies including hyaluronic-acid-based viscosupplementation and surgical regenerative products (e.g., Tactoset, Bone Repair). Comparable on orthopedic regenerative medicine focus and surgical-channel distribution.
• Organogenesis Holdings: Organogenesis is a publicly-traded regenerative medicine company with a portfolio spanning wound care (Apligraf, Dermagraft) and surgical/orthopedic biologics (NuShield, PuraPly). Directly competes with Skye's wound and surgical membrane products in the same hospital/physician channels.
• MiMedx Group: MiMedx is a direct competitor in placental tissue allografts (EpiFix, AmnioFix) serving wound care, surgical, and orthopedic applications. Strong overlap with Skye's HydraTek-based product line, target specialties, and channel approach (physicians, hospitals).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/skye-orthobiologics

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skye Biologics